Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the stock, ...

Rhythm Pharmaceuticals has a 1 year low of $35.17 and a 1 year high of $68.58. The company’s fifty day moving average is $57.26 and its two-hundred day moving average is $53.36. Institutional ...

BOSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare ...

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential Rhythm Pharmaceuticals targets rare obesity disorders with its drug Imcivree, showing strong ...

Rhythm Pharmaceuticals, Inc. (RYTM) shares soared 5.5% in the last trading session to close at $57.52. The move was backed by solid volume with far more shares changing hands than in a normal session.

Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Rhythm Pharmaceuticals (NASDAQ:RYTM) Inc on Wednesday, setting a price target of $43, which is... Morgan Stanley (NYSE ...

Rhythm Pharmaceuticals announced preliminary unaudited net revenues of $42 million for the fourth quarter and $130 million for the full year of 2024, marking significant growth driven by increased ...

BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare ...